ALIPAY
18.5.2022 09:48:09 CEST | Business Wire | Press release
On International Museum Day 2022, 4DAGE announced it landed virtual tours and exhibitions of 23 museums, including the historic Henan Museum and Zhejiang Provincial Museum in China and the Hetjens Museum in Germany, through a mini program on Alipay, the leading digital open platform. The collaboration between 4DAGE and Alipay provides China’s mobile-savvy audience an opportunity to better engage with and learn about the museums’ rich histories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005528/en/
The mini program “Yunshang Mibao” (translated as “treasure hunting on the cloud”) launched on the Alipay platform provides users an immersive museum-visiting experience at their fingertips. They can appreciate the beauty of cultural relics in 3D and have a comprehensive tour of historical collections with Chinese narration.
These virtual exhibitions cover a wide range of subjects spanning 8,000 years of history, including Bronze Age civilization in the Yangtze river valley, dinosaurs in the Mesozoic Era and ceramics in the Rococo period.
“We are delighted to collaborate with museums and the Alipay platform to explore innovative ways to communicate the stories and histories of culture institutions to a wider range of museum and art lovers,” said Shen Ming, Director of International Cooperation from 4DAGE, the VR technology provider for the virtual tours.
“Alipay is committed to supporting the digital operations of brands and merchants to enhance their connection and engagement with consumers in China. Together with our partners, we are exploring digital solutions to meet museums’ evolving needs, including leveraging technology to bring their stories to a younger generation and open new commercialization opportunities,” said Xiaoqi Wang, Head of digital operations for culture and tourism sector at Alipay.
The partnership between 4DAGE and Alipay reflects Alipay’s continued commitment to help museums globally engage and deepen their relationship with China’s growing cultural arts and history community at time when international travel is affected by the COVID-19 pandemic.
To further celebrate this year’s International Museum Day, 28 Chinese museums are issuing newly launched creative digital collectibles on the Alipay mini program and the Topnod app, an Ant Group platform for collecting, exploring, and sharing digital collectibles.
A UNESCO report published in May 2020 showed the global museum industry has been severely impacted by COVID-19 with nearly 90% of museums worldwide closing their doors during the pandemic1 . However, less than 20% of museum collections were available online, according to a report by the Network of European Museum Organisations in July 20202 . Facing the pressing challenges brought by the pandemic, a growing number of museums start to leverage digital platforms and solutions, including online exhibitions, digital tours, and even livestreaming and blockchain technology powered digital collectibles, to better engage with museum lovers.
Including today’s announcement and a recent collaboration with nine Italian museums, over 2,000 museums have landed on the Alipay platform to enhance their digital operations and better connect with museum lovers. These museums are utilising at least one of the digital tools and services available on Alipay, such as mini programs, lifestyle accounts, and blockchain-powered digital collectibles.
About 4DAGE
Founded in 2014, 4DAGE has been dedicated to the studies and application of artificial intelligence in the field of three-dimensional digital reconstruction. As one of the first 3D digital reconstruction centers in China and one of the pioneering companies in 3D display technologies, 4DAGE provides products and solutions to major museums and expositions globally, including the Palace Museum, Nanchang Han Dynasty Haihunhou Historic Site Museum and World Expo. 4DAGE also serves industries ranging from industrial intelligence and smart city to real estate and new retail.
About Alipay
In the evolving digital era, Alipay has transformed from a payment tool of public trust to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operation, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than 1 billion consumers via Alipay’s open platform services.
1
https://cimam.org/documents/102/Museums_around_the_world_in_the_face_of_COVID-19_-_UNESCO_Biblioteca_Digital.pdf
2
https://icom.museum/en/news/online-learning-teaching-digitised-collections/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005528/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom